Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
WHK enters the October 17 week with a striking divergence: short interest has tripled since early October, yet the borrow market remains loose and borrowing costs have eased.
The sharp move in short interest is the headline. Shares short jumped from around 257,000 to more than 843,000 between October 8 and October 12, a 227% rise over the week and roughly 205% above where they stood a month ago. That is a large move in absolute terms for a company of this size. The ORTEX short score reflected the shift immediately, jumping from the high 30s to just above 51 in a single session on October 8, where it has held since. Despite that, the borrow market tells a more relaxed story. Availability runs at 336%, meaning there are more than three shares available to lend for every share currently borrowed, well above the 52-week tightest reading of 181%. Cost to borrow has eased from nearly 7.5% a month ago to 5.5% now. The lending pool is not under pressure. That combination, a tripling of short interest alongside abundant availability and falling borrow costs, suggests the new shorts entered a liquid market and faced no friction doing so.
The Russell 2000 addition provides important context for those positioning numbers. WHK was added to the Russell 2000 during the September 2026 Quarterly Review, with the trade date of September 18 and effective date of September 21. Index trackers had to buy an estimated $73 million worth of WHK shares over roughly 12.7 days of normal trading volume. That mechanical buying created a predictable post-addition dynamic: passive demand clears, price often softens, and shorts who were previously squeezed out by the inclusion flow see an opportunity to rebuild. The stock is down 9.4% over the past month and off 1.1% on the week, closing at $25.96 on October 16.
On the Street, coverage is relatively fresh but limited to one recurring voice. Raymond James analyst John Freeman initiated at Strong Buy in July with a $34 target, raised to $37 in September, then trimmed back to $35 at the start of October, still implying roughly 35% upside from the current price. Capital One carries an Overweight rating with a $32 target. Stifel has a Buy at $30. JP Morgan sits at Neutral with no published target. The consensus mean sits at $32.40. The analyst data is about 15 days old, just past the standard threshold, so treat the specific targets as indicative rather than current. Valuation has been compressing: the trailing PE has dropped sharply, down more than 26 points over 30 days to 38.5x, and EV/EBITDA has drifted lower to 8.7x. Price-to-book stands at 1.5x.
The ownership register carries some notable names. Leon Cooperman filed a Schedule 13G disclosing a 12.4% stake, and Daniel Herz filed at 16.1%, both disclosed in August 2026. Horizon Kinetics holds 6.8% per a July 2026 filing. These are passive-intent filings rather than activist positions, and as the disclosure caveat notes, stakes are as last disclosed around the 5% threshold. T. Rowe Price shows 5.5% in June 2026 data. No 13D activist is on the register. The insider record over the past 90 days shows net zero open-market activity. The August filings were grant transactions coded as awards, not discretionary purchases, carrying limited informational value on sentiment.
Earnings are due November 12. The three most recent post-earnings one-day moves were plus 1.5%, plus 0.35%, and minus 1.5%, a narrow range suggesting the market has not historically treated WHK releases as high-volatility events. The more pressing question heading into that print is whether the post-inclusion short build reflects a genuine fundamental view or simply traders fading the mechanical buying pressure from the Russell addition, a distinction the November numbers may help answer.
See the live data behind this article on ORTEX.
Open WHK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
